Xeltis Reports Preliminary Data For Coronary Artery Bypass Conduit - Data Intelligence
4 Articles
4 Articles
Xeltis Reports Preliminary Data For Coronary Artery Bypass Conduit - Data Intelligence
The EU study aims to assess the Xabg technology in patients with multi-vessel atherosclerotic coronary artery disease who are scheduled for elective CABG surgery. Credit: Photoroyalty / Shutterstock.com. Xeltis has reported positive preliminary data for its Xabg coronary artery bypass conduit (CABG) in a clinical trial that is underway at various European Union (EU) sites. The data from the trial indicated positive safety and patency for individ…
Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial – Optimum Strategic CommunicationsLink to: One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell ProfilingLink to: EIFO an
Preliminary clinical data from Xabg, Xeltis’ coronary artery bypass conduit (CABG), demonstrating positive safety and patency In an earlier, separate trial, Xabg recently demonstrated patency with excellent flow in a 24-month trial – the first time ever this duration has been achieved Supports potential of Xabg to transform CABG surgery landscape and eliminate need for […]
Preliminary data “encouraging” for biorestorative coronary bypass conduit - Cardiovascular News
Xeltis has announced preliminary data for Xabg, its coronary artery bypass conduit (CABG), demonstrating positive safety and patency among patients with multi-vessel atherosclerotic coronary artery disease. Xabg is a novel, biorestorative, polymeric conduit which enables continued blood flow in coronary artery disease patients. Developed using Xeltis’ proprietary Endogenous Tissue Restoration (ETR) platform, Xabg has regenerative properties, ena…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium